Reuters logo
BRIEF-Lilly says neoMONARCH phase 2 trial met primary endpoint of reducing expression of KI67
December 8, 2016 / 1:49 PM / a year ago

BRIEF-Lilly says neoMONARCH phase 2 trial met primary endpoint of reducing expression of KI67

Dec 8 (Reuters) - Eli Lilly and Co :

* Eli Lilly and Co - trial met its primary endpoint of reducing expression of KI67, a biomarker of cell proliferation, after two weeks of treatment

* Eli Lilly-results showed abemaciclib monotherapy, abemaciclib in combination with anastrozole significantly reduced KI67 more than anastrozole alone

* Lilly presents neoMONARCH phase 2 data on abemaciclib in early-stage breast cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below